HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hain rebuked by NASDAQ

This article was originally published in The Rose Sheet

Executive Summary

Staff determination letter sent by NASDAQ Nov. 14 states that Hain Celestials is not in compliance with filing requirements for continued listing due to its failure to timely file Form 10-Q for the fiscal period ended Sept. 30, 2007, firm announces Nov. 16. An independent review of the company's stock option practices, launched last September, is "substantially complete" but has delayed the filing of the 10-Q, as well as its Annual Report on Form 10-K for the year ended June 30, 2007 (1"The Rose Sheet" Sept. 24, 2007, In Brief). Hain shares remain listed on NASDAQ pending a decision from its Listing Qualifications Panel, with which the company met Oct. 31. Any adjustments that have been identified in its review will not affect the company's previously released results of operations for the fiscal year or quarter in question, the firm says...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel